RISS 학술연구정보서비스

검색

인기 검색어

    다국어 입력

    http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

    변환된 중국어를 복사하여 사용하시면 됩니다.

    예시)
    • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
    • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
    닫기
    KCI등재 SCOPUS

    Chronic lymphocytic leukemia: recent advances and emerging therapeutic strategies

    한글로보기

    https://www.riss.kr/link?id=A110589929

    • 0

      상세조회
    • 0

      다운로드
    서지정보 열기
    • 내보내기
    • 내책장담기
    • 공유하기
      • URL 복사
    • 오류접수
    인용문이 복사되었습니다.

    부가정보

    다국어 초록 (Multilingual Abstract) kakao i 다국어 번역

    Chronic lymphocytic leukemia (CLL) management has evolved into a precision-medicine paradigm, with genetic risk factors such as TP53 and IGHV status serving as key determinants of frontline treatment selection. The therapeutic landscape has expanded to include fixed-duration options alongside established continuous regimens. This expansion has enabled personalized management strategies incorporating measurable residual disease-guided treatment approaches aimed at achieving deeper responses while minimizing long-term toxicity and resistance. In a relapsed/ refractory setting, treatment selection must be guided by prior treatment exposure, identified molecular mechanisms of resistance, and the availability of novel agents. In this review, we have synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL. Furthermore, we examined the clinical efficacy reported in pivotal trials involving patients with relapsed/ refractory CLL and discuss the potential of next-generation therapies, including non-covalent Bruton tyrosine kinase (BTK) inhibitors, BTK degraders, and cellular immunotherapies, to expand treatment options for high-risk patients.
    Finally, we addressed the clinical challenges of Richter’s transformation, emphasizing the importance of clonality assessment and the urgent need for further clinical trials and innovative therapeutic approaches to improve longterm outcomes in this patient population.
    번역하기

    Chronic lymphocytic leukemia (CLL) management has evolved into a precision-medicine paradigm, with genetic risk factors such as TP53 and IGHV status serving as key determinants of frontline treatment selection. The therapeutic landscape has expanded t...

    Chronic lymphocytic leukemia (CLL) management has evolved into a precision-medicine paradigm, with genetic risk factors such as TP53 and IGHV status serving as key determinants of frontline treatment selection. The therapeutic landscape has expanded to include fixed-duration options alongside established continuous regimens. This expansion has enabled personalized management strategies incorporating measurable residual disease-guided treatment approaches aimed at achieving deeper responses while minimizing long-term toxicity and resistance. In a relapsed/ refractory setting, treatment selection must be guided by prior treatment exposure, identified molecular mechanisms of resistance, and the availability of novel agents. In this review, we have synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL. Furthermore, we examined the clinical efficacy reported in pivotal trials involving patients with relapsed/ refractory CLL and discuss the potential of next-generation therapies, including non-covalent Bruton tyrosine kinase (BTK) inhibitors, BTK degraders, and cellular immunotherapies, to expand treatment options for high-risk patients.
    Finally, we addressed the clinical challenges of Richter’s transformation, emphasizing the importance of clonality assessment and the urgent need for further clinical trials and innovative therapeutic approaches to improve longterm outcomes in this patient population.

    더보기

    분석정보

    View

    상세정보조회

    0

    Usage

    원문다운로드

    0

    대출신청

    0

    복사신청

    0

    EDDS신청

    0

    동일 주제 내 활용도 TOP

    더보기

    주제

    연도별 연구동향

    연도별 활용동향

    연관논문

    연구자 네트워크맵

    공동연구자 (7)

    유사연구자 (20) 활용도상위20명

    해외이동버튼